Pharmaceutical giant GSK has agreed to buy US cancer drug firm Nuvalent in a 10.6 billion US dollar (£8 billion) deal as it looks to expand its cancer treatment offering.
The UK group will pay 124 US dollars (£92.71) a share for Nasdaq-listed Nuvalent, which is based in Cambridge, Massachusetts.